Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.